The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease
Open Access
- 15 November 2023
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (11) , e0087423
Abstract
Rifampicin is recommended for the treatment of Mycobacterium avium complex pulmonary disease alongside azithromycin and ethambutol. We evaluated the azithromycin-ethambutol backbone with and without rifampicin in an intracellular hollow fiber model and performed RNA sequencing to study the differences in adaptation. In an in vitro hollow fiber experiment, we simulated epithelial lining fluid pharmacokinetic profiles of the recommended 3-drug (rifampicin, ethambutol, and azithromycin) or a 2-drug (ethambutol and azithromycin) treatment. THP-1 cells infected with M. avium ATCC700898 were exposed to these regimens for 21 days. We determined intra- and extra-cellular bacterial load- and THP-1 cell densities on days 0, 3, 7, 14, and 21, alongside RNA sequencing. The emergence of macrolide resistance was studied by inoculating intra- and extra-cellular fractions of azithromycin-containing Middlebrook 7H10 agar plates. Complete pharmacokinetic profiles were determined at days 0 and 21. Both therapies maintained stasis of both intra- and extra-cellular bacterial populations for 3 days, whilst regrowth coinciding with the emergence of a macrolide-resistant subpopulation was seen after 7 days. THP-1 cell density remained static. Similar transcriptional profiles were observed for both therapies that were minimally influenced by exposure duration. Transcriptional response was slightly larger during 2-drug treatment. Rifampicin did not add to the antimycobacterial effect to the 2-drug therapy or suppression of emergence resistance. RNA transcription was not greatly altered by the addition of rifampicin, which may be due to strong transcriptional influence of azithromycin and host cells. This questions the role of rifampicin in the currently recommended therapy. These findings should be confirmed in clinical trials.Keywords
Funding Information
- RUNMC | Radboud Institute for Health Sciences
This publication has 32 references indexed in Scilit:
- Epidemiology of Human Pulmonary Infection with Nontuberculous MycobacteriaClinics in Chest Medicine, 2015
- Macrolide/Azalide Therapy for Nodular/Bronchiectatic Mycobacterium avium Complex Lung DiseaseChest, 2014
- Efficacy of Clarithromycin and Ethambutol for Mycobacterium avium Complex Pulmonary Disease. A Preliminary StudyAnnals of the American Thoracic Society, 2014
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Clinical and Molecular Analysis of Macrolide Resistance in Mycobacterium avium Complex Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Effect of Sex and AIDS Status on the Plasma and Intrapulmonary Pharmacokinetics of RifampicinClinical Pharmacokinetics, 2004
- A Prospective, Randomized Trial Examining the Efficacy and Safety of Clarithromycin in Combination with Ethambutol, Rifabutin, or Both for the Treatment of Disseminated Mycobacterium avium Complex Disease in Persons with Acquired Immunodeficiency SyndromeClinical Infectious Diseases, 2003
- Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2003
- A Randomized, Placebo‐Controlled Study of Rifabutin Added to a Regimen of Clarithromycin and Ethambutol for Treatment of Disseminated Infection with Mycobacterium avium ComplexClinical Infectious Diseases, 1999